Interleukin-17 receptor C gene polymorphism reduces treatment effect and promotes poor prognosis of ischemic stroke

Area of Science:

• Genetics and Molecular Biology
• Neurology
• Immunology

Background:

• Interleukin-17 receptor C (IL-17RC) plays a role in inflammatory responses.
• Gene polymorphisms can influence susceptibility and outcomes in various diseases.
• Ischemic stroke (IS) is a significant global health concern with complex underlying mechanisms.

Purpose of the Study:

• To investigate the association between Interleukin-17 receptor C (IL-17RC) gene polymorphism and ischemic stroke (IS).
• To evaluate the correlation between IL-17RC gene variants and clinical outcomes in IS patients.

Main Methods:

• Quantitative real-time PCR (qRT-PCR) and Western blotting were used to measure mRNA and protein levels of IL-17 and IL-17RC.
• Polymerase chain reaction (PCR) amplification was employed for IL-17RC genotyping.
• Case-control study involving 300 IS patients and 300 healthy controls.

Main Results:

• Elevated mRNA and protein levels of IL-17 and IL-17RC were observed in IS patients compared to controls.
• A significantly higher proportion of the IL-17RC re37511 polymorphism was found in the IS group.
• The IL-17RC re37511 variant was associated with poorer treatment effects, higher mortality, and recurrence rates.

Conclusions:

• Ischemic stroke is associated with upregulated IL-17 and IL-17RC expression.
• The IL-17RC re37511 polymorphism serves as a potential indicator of poor prognosis and treatment response in IS.